Xuanzhu Biopharmaceutical Co., Ltd. (SEHK: 2575)
Health Care · Pharmaceuticals · CN
HK$12.36
-4.04% today · -53.0% 1Y
Xuanzhu Biopharmaceutical Co., Ltd. (SEHK: 2575) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $815.79M and employs 342 people.
Over the last twelve months the share price has lost 53.0%, trading between 10.60 and 96.90.
Tweenvest scores Xuanzhu Biopharmaceutical Co., Ltd. across four factors: quality 35/100. Its strongest factor is quality.
2575 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $815.79M
- Revenue (TTM)
- $7.40M
- P/E
- —
- EPS
- -0.53
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$96.90
- 52-week low
- HK$10.60
- Avg volume (3M)
- —
- Shares outstanding
- 517.95M
- Employees
- 342
- Next earnings
- —
About Xuanzhu Biopharmaceutical Co., Ltd.
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.
- ISIN
- CNE1000074Q1
- Founded
- 2008
- Listed since
- Oct 15, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.